Status:
RECRUITING
Evaluating the Impact of Social and Genetic Factors on Outcomes in Adolescent and Young Adult Cancer Survivors
Lead Sponsor:
ECOG-ACRIN Cancer Research Group
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Hodgkin Lymphoma
Non-Hodgkin Lymphoma
Eligibility:
All Genders
18+ years
Brief Summary
This study examines the impact of social and genetic factors on outcomes in adolescent and young adult (AYA) cancer survivors of Hodgkin or non-Hodgkin lymphoma. Compared to both older adult and child...
Detailed Description
PRIMARY OBJECTIVE: I. To establish the association of social-environmental risk factors on both disease-free survival (DFS) and overall survival (OS) for adolescent and young adult cancer survivors. ...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Patient must be \>= 18 years of age at the time of registration
- Patient must have been between the ages of 15-39 at the time of their first primary cancer diagnosis of Hodgkin lymphoma or non-Hodgkin lymphoma (NHL)
- Patient must have completed therapy (with a complete response, per clinician determination) at the time of registration
- Patients last date of prior systemic therapy for first primary diagnosis for Hodgkin lymphoma or non-Hodgkin lymphoma must have been within one year prior to registration
- NOTE: Systemic therapy refers to all anti-cancer therapy, including but not limited to chemotherapy, intravenous (IV) or oral targeted medications, or radiation, and administered via a clinical trial or standard approach
- Patient must have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-3
- Patient must be English speaking in order to be able to complete the required QOL forms on this study
- NOTE: Sites cannot translate the associated QOL forms
- Patient must not be receiving active therapy for Hodgkin lymphoma or non-Hodgkin lymphoma
- Patient must have internet access through computer, tablet, or smartphone
- Patient must have email address
- Patient must have the ability to understand and the willingness to sign a written informed consent document. Patients with impaired decision-making capacity (IDMC) who have a legally authorized representative (LAR) or caregiver and/or family member available will also be considered eligible
Exclusion
Key Trial Info
Start Date :
October 13 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
February 1 2030
Estimated Enrollment :
2000 Patients enrolled
Trial Details
Trial ID
NCT06002828
Start Date
October 13 2023
End Date
February 1 2030
Last Update
December 30 2025
Active Locations (428)
Enter a location and click search to find clinical trials sorted by distance.
1
Anchorage Associates in Radiation Medicine
Anchorage, Alaska, United States, 98508
2
Anchorage Radiation Therapy Center
Anchorage, Alaska, United States, 99504
3
Alaska Breast Care and Surgery LLC
Anchorage, Alaska, United States, 99508
4
Alaska Oncology and Hematology LLC
Anchorage, Alaska, United States, 99508